This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Methyltestosterone and Meth-Dia-Mer-Sulfonamides

JOHN H. LAMB, M.D.; Gerbert Rebell; Phyllis E. Jones, M.D.; Robert J. Morgan, M.D.; John M. Knox, M.D.

AMA Arch Derm Syphilol. 1954;70(6):695-712.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THERE IS no reported instance of treatment of systemic fungous disease in man with testosterone compounds. In 1953 Lamb and his associates¹ reported the cure of a mycetoma caused by an atypical Nocardia under treatment with large doses of pregnenolone acetate. Trial of this steroid in disseminated coccidioidomycosis has been unsuccessful.^* The use of aromatic diamidines structurally related to synthetic estrogens is being thoroughly investigated by Curtis and his co-workers.²

The present paper presents in vitro and in vivo laboratory studies of testosterone compounds as fungistatic agents and a report of the clinical trial of methyltestosterone and meth-dia-mer-sulfonamides (triple sulfonamides) in three cases of the deep mycoses.

LABORATORY ASSAY OF ANTIMYCOTIC EFFECT OF TESTOSTERONE COMPOUNDS AND SULFONAMIDES

In Vitro Assay of Testosterone, Methyltestosterone, and Testosterone Propionate.—In 1949 Reiss³ demonstrated that testosterone, methyltestosterone, and other steroids and steroid-like compounds possess moderate fungistatic activity in vitro against Histoplasma capsulatum and other pathogenic fungi. Using a pour . . . [Full Text PDF of this Article]

Author Affiliations
OKLAHOMA CITY

Footnotes
Read before the 74th Annual Meeting of the American Dermatological Association, Inc., White Sulphur Springs, W. Va., April 17, 1954.

Dr. Knox, formerly of Oklahoma City, is now in the Department of Dermatology, University Hospital, University of Michigan Medical School.

This investigation was made with the assistance of the National Cancer Institute, Dome Chemicals, Inc., New York; Eaton Laboratories, Inc., Norwich, N. Y.; Duke Laboratories, Inc., Stamford, Conn.; The Committee on Research of the Council on Pharmacy and Chemistry of the American Medical Association, and the Everett S. Lain Dermatological Fund of the Oklahoma Medical Research Foundation. Laboratory space was provided in the Dermatologic Section of the Oklahoma Medical Research Foundation Building.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?